Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3

Trial Identifier: EFC17215
Sponsor: Sanofi
Start Date: April 2022
Primary Completion Date: October 2025
Study Completion Date: October 2026
Condition: Gaucher Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Argentina Buenos Aires, Argentina, 1426
Canada, Manitoba Winnipeg, Manitoba, Canada, R3E 3P4
China Beijing, China, 100005
China Guangzhou, China, 510080
China Shanghai, China, 200092
China, Taiwan Taipei, Taiwan, China, 10041
France Paris, France, 75015
France Paris, France, 75013
Germany Hochheim am Main, Germany, 65239
Hungary Debrecen, Hungary, H-4032
Italy Napoli, Italy, 80131
ITALY, Lombardia Milano, Lombardia, ITALY, 20122
Japan Sendai, Japan, 980-8574
JAPAN, Kanagawa Odawara, Kanagawa, JAPAN, 250-8558
TURKEY ADANA, TURKEY, 01790
TURKEY Ankara, TURKEY, 06500
TURKEY Istanbul, TURKEY, 34093
UNITED KINGDOM London, UNITED KINGDOM, NW3-2PF
United States, Connecticut New Haven, Connecticut, United States, 06511
United States, Iowa Iowa City, Iowa, United States, 52242
United States, Virginia Fairfax, Virginia, United States, 22030
UNITED STATES, Texas Dallas, Texas, UNITED STATES, 75230